Klinische Studie

Phase ii multicenter study of extracorporeal photopheresis with uvadextm plus standard steroid treatment for high risk acute graft-versus-host disease(MAGIC-HR-ECP)Multicenter study of extracorporeal photophoresis with UVADEX plus standard steroid treatment for high risk acute Graft-versus-host-disease
EUDRACT2019-000894-22
NCTNCT04291261
DRKS-
Krankheitsentität(en) Blut (Leukämie), Lymphknoten, Knochenmark
Darm (Dickdarm, Mastdarm)
übergreifende Studien
StudientypInterventionsstudiePhase II
Wesentliche EinschlusskriterienNew onset high risk acute GvHD Ann Arbor score 2 or 3 following allogenic SCT Any donor type No prior systemic treatment for acute GvHD expect for a max. of 7 days of methylprednisolone Age 18 or older Platelet count > 25.000
Wesentliche AusschlusskriterienProgressive or relapsed malignancy Uncontrolled active infection patients with chronic GvHD History of or current diagnosis of progressive mulitfocal leukencephalopathy Pregnangt or nursing women
StatusStudie beendet
Ansprechpartner & KontaktUniversitätsklinikum RegensburgInnere Medizin IIIStudienzentrale0941 944 -15535 / -18249studienzentrale.med3(at)ukr.de
zurück